The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse Gastroprotective agent compliance in patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer with NSAID in France
- collapse A randomized, double-blind, parallel group multicenter efficacy and safety phase IIB pilot study of Esomeprazole 40mg bid versus placebo bid in adult asthmatics treated for 4 months.
- collapse What is the value of the use of validated questionnaire (Reflux Impact Scale) for predicting treatment success with PPI.
- collapse A Multicenter, double -blind, Placebo-controlled Study to evaluate the effects of Esomeprazole 40mg bid on the signs and symptoms of Chronic Posterior Laryngitis with suspected Laryngopharyngeal Reflux.
- collapse Using an electronic health record-based intervention and broad education reach strategies to improve quality of care for GERD and gastroprotection for patients on NSAIDs: a randomized controlled trial
- collapse An epidemiological, observational study to describe symptom control and impact on daily life of GERD in patients with erosive gastroesophageal reflux disease.
- collapse Long Term Study to Investigate the Efficacy & Safety of D961H for the Prevention of NSAIDs-induced Ulcer
- collapse Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France (REMAIN)
- collapse A randomized, double-blind, parallel-group, multicentre, phase III study to assess the effect of esomeprazole 20 and 40 mg od versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous lowdose acetylsalicylic acid (ASA).
- collapse A Phase I, open-label, randomized, two way crossover pharmacokinetic study comparing the bioavailability of acetylsalicylic acid (ASA) after 5 days repeated once daily administration of a fixed dose combination capsule of ASA 81 mg/esomeprazole 20 mg and ASA 80 mg (European aspirin reference product) in Healthy Male and Female Volunteers
